Document is current
Any future updates will be listed below
-
Authors
Yang, Lin https://orcid.org/0000-0003-2372-7547
Wang, Jin
Altreuter, Jennifer https://orcid.org/0000-0001-6545-6496
Jhaveri, Aashna
Wong, Cheryl J. https://orcid.org/0000-0003-2070-7495
Song, Li
Fu, Jingxin
Taing, Len
Bodapati, Sudheshna
Sahu, Avinash https://orcid.org/0000-0002-2193-6276
Tokheim, Collin
Zhang, Yi https://orcid.org/0000-0002-7453-6188
Zeng, Zexian
Bai, Gali
Tang, Ming
Qiu, Xintao https://orcid.org/0000-0002-8560-7017
Long, Henry W. https://orcid.org/0000-0001-6849-6629
Michor, Franziska
Liu, Yang https://orcid.org/0000-0001-6979-2518
Liu, X. Shirley
-
Funding
Funding for this research was provided by:
Foundation of National Institute of Health
- License Information
-
More Information
Article History
Received: 7 January 2022
Accepted: 22 February 2023
First Online: 30 June 2023
Change Date: 17 July 2023
Change Type: Update
Change Details: In the verzion of this article initially published, the alternating color groups in the Table 1 "Tasks" rows were offset and are now corrected in the HTML and PDF versions of the article.
Competing interests
: X.S.L. conducted the work while being on the faculty at the Dana-Farber Cancer Institute and is currently a board member and CEO of GV20 Therapeutics. F.M. is a cofounder of and has equity in Harbinger Health, has equity in Zephyr AI and serves as a consultant for Harbinger Health, Zephyr AI and Red Cell Partners. F.M. declares that none of these relationships are directly or indirectly related to the content of this manuscript. All other authors do not have any conflicts.
